Jafron Biomedical Co.,Ltd. (300529.SZ)
CNY 30.04
(-0.07%)
CNY 30.04
(-0.07%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.92 Billion CNY | -22.84% |
| 2022 | 2.49 Billion CNY | -6.88% |
| 2021 | 2.67 Billion CNY | 37.15% |
| 2020 | 1.95 Billion CNY | 36.24% |
| 2019 | 1.43 Billion CNY | 40.86% |
| 2018 | 1.01 Billion CNY | 41.48% |
| 2017 | 718.49 Million CNY | 32.16% |
| 2016 | 543.64 Million CNY | 6.83% |
| 2015 | 508.9 Million CNY | 37.19% |
| 2014 | 370.93 Million CNY | 22.18% |
| 2013 | 303.58 Million CNY | 21.13% |
| 2012 | 250.62 Million CNY | 28.53% |
| 2011 | 194.98 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 732.67 Million CNY | 67.9% |
| 2024 Q3 | 700.06 Million CNY | -5.27% |
| 2024 Q2 | 738.98 Million CNY | 0.86% |
| 2023 FY | 1.92 Billion CNY | -22.84% |
| 2023 Q4 | 436.36 Million CNY | -7.91% |
| 2023 Q3 | 473.83 Million CNY | 7.79% |
| 2023 Q1 | 572.55 Million CNY | 22.94% |
| 2023 Q2 | 439.58 Million CNY | -23.22% |
| 2022 Q3 | 471.41 Million CNY | -44.99% |
| 2022 FY | 2.49 Billion CNY | -6.88% |
| 2022 Q2 | 856.93 Million CNY | 22.88% |
| 2022 Q1 | 697.35 Million CNY | -21.97% |
| 2022 Q4 | 465.73 Million CNY | -1.2% |
| 2021 FY | 2.67 Billion CNY | 37.15% |
| 2021 Q1 | 578.9 Million CNY | -8.9% |
| 2021 Q4 | 893.64 Million CNY | 50.56% |
| 2021 Q3 | 593.55 Million CNY | -2.59% |
| 2021 Q2 | 609.35 Million CNY | 5.26% |
| 2020 Q4 | 635.44 Million CNY | 42.59% |
| 2020 Q3 | 445.65 Million CNY | -9.2% |
| 2020 FY | 1.95 Billion CNY | 36.24% |
| 2020 Q1 | 378.88 Million CNY | -17.73% |
| 2020 Q2 | 490.79 Million CNY | 29.54% |
| 2019 Q1 | 295.16 Million CNY | -7.3% |
| 2019 Q2 | 363.67 Million CNY | 23.21% |
| 2019 Q4 | 460.54 Million CNY | 47.41% |
| 2019 FY | 1.43 Billion CNY | 40.86% |
| 2019 Q3 | 312.42 Million CNY | -14.09% |
| 2018 Q4 | 318.4 Million CNY | 31.67% |
| 2018 Q2 | 249.72 Million CNY | 20.9% |
| 2018 Q1 | 206.55 Million CNY | -8.89% |
| 2018 FY | 1.01 Billion CNY | 41.48% |
| 2018 Q3 | 241.82 Million CNY | -3.17% |
| 2017 Q4 | 226.69 Million CNY | 38.8% |
| 2017 Q1 | 147.96 Million CNY | -13.03% |
| 2017 FY | 718.49 Million CNY | 32.16% |
| 2017 Q2 | 180.5 Million CNY | 21.99% |
| 2017 Q3 | 163.32 Million CNY | -9.52% |
| 2016 Q2 | 134.3 Million CNY | 6.94% |
| 2016 FY | 543.64 Million CNY | 6.83% |
| 2016 Q4 | 170.14 Million CNY | 49.77% |
| 2016 Q3 | 113.59 Million CNY | -15.42% |
| 2016 Q1 | 125.59 Million CNY | -23.36% |
| 2015 FY | 508.9 Million CNY | 37.19% |
| 2015 Q4 | 163.88 Million CNY | 33.06% |
| 2015 Q3 | 123.16 Million CNY | 2.91% |
| 2015 Q2 | 119.67 Million CNY | 17.12% |
| 2015 Q1 | 102.18 Million CNY | 0.0% |
| 2014 FY | 370.93 Million CNY | 22.18% |
| 2013 FY | 303.58 Million CNY | 21.13% |
| 2012 FY | 250.62 Million CNY | 28.53% |
| 2011 FY | 194.98 Million CNY | 0.0% |